Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5918_Библиотеки_им_академика_М_И_Перельмана
.pdf
11 Role ofGenomics andProteomics inDrug Discovery
https://t.me/med1917
proteomic data. Finding lead compounds that can be developed further into medication candidates requires the use of HTS (Wildey etal. 2017). The creation of small
compounds or biologics that specically interact with the target and modulate its
activity can be guided by the 3D structures of veried therapeutic targets, which
were discovered by structural proteomic approaches. The development of targeted
therapeutics, in which medications are created to specically hit a particular target
with few off-target effects, depends heavily on proteomic data (Wang etal. 2005).
Drug candidate efcacy in disease contexts is validated using animal models and
cell-based assays. To evaluate changes in protein expression and activity in response
to the treatment, proteomics is used. These studies support the validity of the target’s and medication candidates’ potential therapeutic usefulness (Filiou et al.
2011). Proteomic approaches can be used to validate the clinical relevance of phar-
macological targets that advance to the clinical development stage. Here, target
expression in patient samples is evaluated, and its relationship to therapeutic outcomes is examined (Ni etal. 2015).
By offering a systematic and data-driven method for choosing the most promising targets, proteomics in target identication and validation speeds up the drug
discovery process. It assists in ensuring that possible therapeutic targets are both
clinically and physiologically meaningful. Proteomic technologies will become
more and more important in the creation of innovative treatments and the advancement of precision medicine as they continue to improve.
219
11.4 Biomarker Discovery
11.4.1 Importance ofBiomarkers inDrug Development
Biomarkers are quantiable indications that reveal details about different biological
processes, ailments, or disorders. Biomarkers are essential tools in the drug development process that provide information on the security, effectiveness, and mode of
action of proposed medications (Kraus 2018). They are crucial because they greatly
speed up and enhance the drug development process in the following ways.
Biomarkers can help in early disease identication and diagnosis, enabling
prompt intervention and therapy. For diseases such as cancer, Alzheimer’s disease,
and cardiovascular illnesses, for instance, certain proteins or genetic markers can be
used as diagnostic biomarkers. Biomarkers are essential for identifying and verifying pharmacological targets. Researchers can identify possible biological targets for
drug development by examining biomarkers linked to a specic disease. Using illness features, genetics, or therapy responsiveness as criteria, biomarkers can assist
in dividing patients into subgroups. This makes it possible to create personalized,
targeted therapy for each patient.
Biomarkers offer a quantitative and unbiased way to evaluate a drug’s effectiveness. Researchers can identify whether a medicine is having the desired therapeutic
effect by observing changes in particular biomarkers. Biomarkers are used to track
220
https://t.me/med1917
the safety of medications and evaluate any potential side effects. Particular biomarkers may show organ damage, metabolic abnormalities, or other drug-related toxicities. By assisting researchers in locating lead compounds and evaluating their
efcacy and safety earlier in the pipeline, biomarkers hasten the medication development process. As a result, developing drugs takes less time and money.
The idea of personalized medicine is based on biomarkers. Biomarkers can
improve treatment effectiveness and reduce negative effects by customizing therapies to each patient’s particular genetic and molecular prole. By easing patient
selection, stratication, and endpoint assessment, biomarkers support the design of
clinical trials. Clinical studies as a result are more effective and instructive. When
reviewing new drug applications, regulatory organizations such as the Food and
Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly taking biomarker data into account. Evidence based on biomarkers can speed
up the regulatory approval procedure.
Biomarkers enable clinicians to keep track of patients’ responses both during and
after pharmacological therapy. This aids in modifying treatment plans and evaluating long-term results. It can cut the price of drug development and prevent late-stage
failures by enabling the early detection of dangerous or inefcient therapeutic candidates. Research on biomarkers helps us better understand how diseases work, and
that knowledge can help us create new therapeutic strategies.
In conclusion, biomarkers are crucial to medication development at every
stage, from target identication to clinical trials and post-market surveillance.
They improve the speed, accuracy, and safety of drug development procedures,
which eventually results in the identication and approval of safer and more
potent medicines. The landscape of drug development and personalized medicine
is still being shaped by the ongoing developments in biomarker research and
technology.
J. Sundarasekar and G. Sahgal
11.4.2 Genomic andProteomic Approaches
toBiomarker Discovery
The early detection, diagnosis, prognosis, and treatment of diseases all depend on
biomarkers. The identication of particular molecular markers connected to a variety of medical disorders has been made possible by genomic and proteomic methods, which have revolutionized the area of biomarker research (Huizar etal. 2020).
In order to nd certain genetic differences linked to diseases, genomic biomarkers
analyse a person’s DNA.This can include copy number variations (CNVs), insertions/deletions, and single-nucleotide polymorphisms (SNPs). Genome-wide association studies (GWAS) can be used to nd genetic variations linked to certain
diseases by analysing the entire genome. Researchers can identify potential genetic
biomarkers by contrasting the genomes of people with a disease and those
without one.
11 Role ofGenomics andProteomics inDrug Discovery
https://t.me/med1917
221
Next-generation sequencing (NGS) enables a thorough examination of a person’s DNA.Using whole-genome and whole-exome sequencing, it is possible to
nd genetic variations that can be used as biomarkers for disease susceptibility and
hereditary disorders. The study of gene expression patterns in various disease states
is the main objective of transcriptomics. Changes in RNA levels can serve as biomarkers for disease diagnosis and prognosis, and these changes can be detected
using microarrays and RNA sequencing (RNA-Seq). Additionally, epigenomics
investigates how variations in histone modications, non-coding RNA, and DNA
methylation patterns can affect gene expression. Biomarkers for cancer and other
disorders can be derived from altered epigenetic marks (Huizar etal. 2020; He 2006).
The study of proteins, which are more specic indicators of biological processes
and disorders, is referred to as proteomic biomarkers. By monitoring protein levels,
post-translational changes, and interactions, proteomics can detect biomarkers.
Mass spectrometry (MS) is a potent method for nding proteome biomarkers. It can
recognize and measure proteins, their isoforms, and post-translational changes,
making it possible to nd biomarkers linked to disease. To pinpoint individual
antibody- antigen interactions, protein microarrays can be probed with patient samples that contain immobilized proteins. Finding diagnostic and prognostic protein
biomarkers may result from this.
Using targeted proteomics, specic proteins of interest are quantied. High sensitivity and accuracy are achieved by using the techniques of selected reaction monitoring (SRM) and multiple reaction monitoring (MRM). Functional proteomic
studies the role of proteins in various illness conditions. It can uncover possible
biomarkers and reveal the mechanisms driving illness progression. Advanced bioinformatics tools are crucial for analysing the massive amounts of data produced during the proteomic biomarker development process. Our understanding of disease
mechanisms is improved by the integration of genomes and proteomic data (Huizar
etal. 2020; Ion etal. 2016).
However, there are many challenges that need to be addressed and focused on
push this technology in the right direction. Researchers are looking into some areas
that have the potential to drive genomics and proteomics in biomarker discovery.
For example, managing and analysing enormous amounts of genomes and proteomic data are difcult tasks that call for sophisticated computational resources
and tools. To guarantee their dependability and relevance, biomarker candidates
need thorough validation.
Integrating genomes, proteomics, and other “omics” data is essential for gaining
a thorough understanding of disease mechanisms and for the identication of trustworthy biomarkers. New methods in single-cell genomics and proteomics also
allow for the analysis of single cells, revealing details on cellular heterogeneity and
cell-specic biomarkers. The development of targeted medicines, personalized
medicine, and our understanding of the molecular basis of diseases are all being
driven by genomic and proteomic approaches to biomarker identication. With the
potential for better diagnostics, prognostics, and therapies, these technologies have
changed the face of health care. Genomic and proteomic research is likely to
222
https://t.me/med1917
elucidate a variety of new biomarkers that will benet patients and the medical community as a whole as time goes on (Mäbert etal. 2014; Matthews etal. 2016).
J. Sundarasekar and G. Sahgal
11.4.3 Case Studies ofSuccessful Biomarker Utilization
In several medical specialties, biomarkers have been useful in enhancing diagnosis,
choice of therapy, and patient outcomes. Here are a few noteworthy case studies that
demonstrate how biomarkers can be used effectively.
Biomarker: Human epidermal growth factor receptor 2 (HER2) gene amplication and protein overexpression. Case Study: Herceptin, a monoclonal antibody, has
been used to treat HER2-positive breast cancer patients with great success. This
treatment primarily targets cancer cells that are HER2-positive. A one-size-ts-all
strategy for treating breast cancer existed prior to the use of this biomarker. Patients
with HER2-positive breast cancer now have much better survival rates and therapeutic results because of Herceptin (Wilson etal. 2018).
Biomarker: Epidermal growth factor receptor (EGFR) mutations. Case Study:
Patients with particular EGFR mutations in non-small cell lung cancer (NSCLC)
benet from targeted treatments such as getinib and erlotinib. These mutations are
easier to identify, which aids oncologists in choosing the best course of action and
increases response rates and progression-free survival (Codony-Servat etal. 2019).
Biomarker: BCR-ABL fusion gene. Case Study: The introduction of imatinib
(Gleevec) therapy for CML transformed the way that cancer is treated. Imatinib
targets this genetic anomaly’s BCR-ABL fusion protein in particular. Many CML
patients may now properly manage their illness and enjoy regular lives as a result
(Abdulmawjood etal. 2021).
Biomarker: Mutations in the BRCA1 and BRCA2 genes. Case Study: Breast and
ovarian cancer risk are enhanced in the presence of BRCA1 and BRCA2 mutations.
These mutations can be identied, allowing for early discovery and customized
risk-reduction measures. Prophylactic operations and surveillance programmes can
considerably lower the incidence of cancer in high-risk persons (Lee etal. 2014).
Biomarker: PSA levels in blood. Case Study: A common biomarker for prostate
cancer is PSA.It assists in early disease detection and therapy response monitoring.
By detecting prostate cancer at an earlier, more treatable stage, PSA testing has
increased survival rates (Saini 2016).
Biomarker: Haemoglobin A1c (HbA1c) levels. Case Study: A biomarker called
HbA1c is used to track the long-term management of blood sugar in diabetics.
Maintaining ideal HbA1c levels aids in avoiding problems and customizing treatment plans, improving disease management and patient outcomes (Kaiafa
etal. 2021).
Biomarker: Human papillomavirus (HPV) DNA.Case Study: Cervical cancer
screening has been improved by HPV testing. It pinpoints the disease’s high-risk
HPV subtypes, enabling early detection and treatment. The prevalence of cervical
cancer has dramatically decreased as a result of this strategy (Shah etal. 2020).
11 Role ofGenomics andProteomics inDrug Discovery
https://t.me/med1917
223
These case studies highlight the signicant inuence that biomarkers have on
diagnosing diseases, choosing treatments, and providing for patients. By enabling
personalized medicine, early diagnosis, and focused therapies, the use of biomarkers has changed the face of health care, ultimately enhancing patient outcomes and
quality of life. The pursuit of new biomarkers promises to provide more indicators
that will continue to inuence medical advancements.
11.5 Target Identication andValidation
11.5.1 Identifying Potential Drug Targets Through Genomics
andProteomics
A crucial phase in the drug discovery process is the identication of prospective
therapeutic targets, and genomics and proteomics have completely changed this
area of pharmaceutical research. These cutting-edge technologies have sped up the
identication of new therapeutic targets and aided in the creation of more accurate
and potent medications.
Genomic and proteomic approaches in identifying drug targets are the same as
the approaches to biomarker discovery as discussed in Sect. 11.4.2. The following
is a gure showing the list of approaches in genomics and proteomic drug targeting
(Kramer and Cohen 2004; Sleno and Emili 2008) (Fig.11.1 and 11.2).
For a thorough understanding of prospective therapeutic targets, the combination
of genomes and proteomic data is crucial. The identication of genes and proteins
that are consistently linked to disease and are functionally relevant is made possible
by the combination of genetic information (genomics) with data on protein expression (proteomics). Finding high-condence pharmacological targets is where this
integrated method excels.
In conclusion, genomics and proteomics have changed the way prospective therapeutic targets are found. By enabling the identication of therapeutic targets at the
genetic and protein levels, these technologies improve the accuracy and efciency
of drug development. The convergence of these two elds, together with developments in computational biology and bioinformatics, continues to spur drug discovery innovation and raises the prospect of more successful and focused treatments in
the future.
Fig. 11.1 Approaches in
genomic drug targeting
1.Genome-Wide
Associaon
Studies (GWAS)
1.Transcriptomics 1.Epigenomics
1.Next-Generaon
Sequencing (NGS)
224
https://t.me/med1917
J. Sundarasekar and G. Sahgal
Fig. 11.2 Approaches in
proteomic drug targeting
1.Proteome
Profiling
1.Funconal
Proteomics
1.Protein
Interacon
Networks
1.Structural
1.Mass
Spectrometry
(MS)
Proteomics
11.5.2 Validation ofDrug Targets
A crucial phase in the drug development process is validating drug targets. It entails
proving that a particular biological molecule, frequently a protein, is not only connected to a disease but also offers a promising target for therapeutic action. Target
validation makes sure that resources are used wisely and that there is a good chance
that the drug development process will succeed. The main elements and techniques
involved in validating pharmacological targets are listed below (Uitdehaag
etal. 2012).
Genetic and genomic evidence such as genetic associations, loss-of-function
studies, and gain-of-function studies can be used in the validation of drug targets.
Genome-wide association studies (GWAS), for example, can nd genetic variants
linked to a disease. These studies give solid evidence for validation if a target gene
or protein is repeatedly connected to a certain ailment.
Loss-of-function studies such as genetic knockout experiments in cellular systems or model organisms can show that a target is required for the development of
a disease. The disease phenotype should be prevented or improved by the absence
of the target. In gain-of-function studies, by overexpressing a gene or protein as a
therapeutic target, researchers can track the emergence or aggravation of disease
symptoms (Minikel etal. 2020).
Biochemical and cellular evidence can also be used in the validation of drug
targets. Proteomic methods can show variations in the levels of protein expression,
post-translational alterations, and connections linked to the disease. Its validation is
aided by repeated changes in the target protein. By creating functional assays to
gauge the target protein’s activity in disease-related pathways, it is possible to conrm the protein’s role in pathogenesis (Waduge etal. 2022).
Drug validation can also be studied by using preclinical models. Using animal
models, researchers can examine the effects of target modulation (such as inhibition
or activation) on the development of disease. Positive outcomes in animals provide
evidence that therapeutic intervention in humans may be effective. Alternatively, in
a controlled setting, the effects of targeting the protein can be evaluated using cultured cells or cell lines obtained from patients (Lacombe etal. 2011).
Pharmacological evidence can be used to validate drug targets. In preclinical
models, the potential of small molecules to modify the disease can be explored by
using chemical probes. These compounds must specically interact with the target
protein. These chemical probes serve as instruments for validating targets. The creation of drug candidates that target the validated molecule can add to the evidence
11 Role ofGenomics andProteomics inDrug Discovery
https://t.me/med1917
supporting the validity of the molecule as a therapeutic target. The drugs’ effectiveness and safety in both preclinical models and clinical trials add to the target’s validity (Roy 2018).
Examining patient tissues and samples for the presence and activity of the target
protein, as well as its relationship to the severity or prognosis of the condition, is a
straightforward means to conrm the target’s applicability to human biology. The
strongest support for this theory comes from medications that successfully treat the
molecule in clinical trials. These studies evaluate the safety, effectiveness, and dosage in patients, further demonstrating the target’s function in the treatment of disease (Lee etal. 2005).
Finding biomarkers linked to the target can act as an indirect form of validation.
These biomarkers may alter in response to target modulation, which can be a sign
of a successful treatment (Kraus 2018). To verify a pharmacological target, several
lines of evidence from several methodologies (genetic, biochemical, preclinical
models, and clinical trials) should ideally converge. Cross-validation supports the
argument that the target is appropriate.
The pharmaceutical industry has difculties guaranteeing that the chosen targets
are both physiologically and therapeutically relevant because the validation of pharmacological targets is a continuous process. When a target is not validated, expensive drug research efforts may be abandoned. However, the establishment of
innovative medicines that can lessen disease burden and enhance patient outcomes
is made possible by the successful validation of a target. The precision and effectiveness of target validation continue to be improved by developments in genetics,
proteomics, and drug discovery technologies.
225
11.5.3 Role ofBioinformatics inTarget Validation
Target validation is a vital phase in the drug discovery process, and bioinformatics is
essential to this process. Target validation seeks to establish the viability and relevance of a particular biological molecule—often a protein—as a target for therapeutic intervention. This procedure is streamlined and improved by bioinformatics,
which makes use of computer tools, data analysis, and integration of multiple “omics”
data. Here is how bioinformatics helps validate targets (Jiang and Zhou 2005).
Bioinformatics tools enable researchers to merge data from the domains of
genomics, transcriptomics, proteomics, and other “omics”. A more complete picture of a target’s participation in a disease can be revealed by integrating these various multi-omics datasets. Bioinformatics software may associate genes and proteins
with certain networks and pathways, assisting researchers in comprehending how
the target functions within the broader scheme of disease-related activities (Wang
etal. 2021).
Bioinformatics also makes it easier to nd genes and proteins that express themselves differently in healthy and diseased conditions. Prioritizing prospective therapeutic targets is made easier by analysing extensive differential expression data.
226
https://t.me/med1917
Bioinformatics can as well identify potential interaction partners and downstream
effectors by analysing the patterns of co-expression of a target gene or protein with
others (Jiang and Zhou 2005).
Bioinformatics tools offer functional annotation and enrichment analysis, helping to evaluate the functions of target genes or proteins in cellular processes and
pathways associated with disease (Lin etal. 2017). Using bioinformatics approach,
it is possible to build protein-protein interaction networks, which can show how
connected a target is to other proteins in a larger landscape of protein-protein interactions. Understanding the regulatory components that regulate a target gene or
protein, such as transcription factors or microRNAs, can shed light on the molecular
processes behind disease (Chen etal. 2016). In text mining, the software uses natural language processing techniques to glean pertinent data from the scientic literature. This aids researchers in collecting data from published studies that show a
target is related to disease (Zheng etal. 2019).
In comparative genomics, genomes from different species may be compared
thanks to bioinformatics. Genes or proteins that have undergone evolutionary conservation are frequently more likely to be crucial for biological processes and make
for desirable targets (Wright etal. 2013). By combining genetic and molecular data
with clinical data, it is possible to nd associations between target expression or
variation and patient outcomes, assisting in target validation for personalized therapy (Yang etal. 2012). Using a variety of factors, including biological relevance,
druggability, and specicity, bioinformatics tools may rank and score candidate
drug targets (Mathai etal. 2020). Bioinformatics in silico drug screening method
also enables virtual testing of small compounds against target protein 3D structures.
The validated target’s prospective medication candidates are identied through this
method (Rao and Srinivas 2011).
Bioinformatics technologies produce visual representations of data, facilitating
the analysis of large datasets and the production of insightful ndings by researchers (Koscielny etal. 2017). Target validation is accelerated by bioinformatics thanks
to its organized and data-driven methodology. It aids decision-making by researchers regarding the applicability and signicance of particular targets for drug development. Bioinformatics expedites the discovery of interesting drug targets by
combining enormous volumes of biological data with powerful computer approaches
and ultimately aids in the creation of safer and more effective medicines.
J. Sundarasekar and G. Sahgal
11.6 High-Throughput Screening
11.6.1 Automation andRobotics
inHigh-Throughput Screening
High-throughput screening (HTS): A crucial stage in the drug development process
is HTS, which entails evaluating a large number of chemical compounds or biological agents for possible therapeutic candidates. This procedure has been transformed
11 Role ofGenomics andProteomics inDrug Discovery
https://t.me/med1917
227
by the use of automation and robotics in HTS, making it quicker, more economical,
and more efcient. This is how robotics and automation are changing HTS.
Automation via increased throughput makes it possible to handle multiple samples at once, which greatly expands the number of chemicals that can be screened in
a shorter amount of time. This speed is necessary to nd promising medication
candidates quickly (Wildey etal. 2017). Dispensing reagents and samples using
automated equipment is extremely accurate and consistent, which minimizes human
mistakes. Ensuring the quality of data and generating dependable outcomes depend
heavily on this reproducibility. Assays can be made smaller by using fewer amounts
of chemicals and reagents thanks to automation. This allows for the screening of
rare or costly molecules while also conserving resources (Mayr and Bojanic 2009).
A vast array of HTS assays can be performed by robotic systems, which are exible and easy to program. They are appropriate for different phases of drug development since they can handle a variety of plate layouts and test types. Automation
makes it feasible to include imaging systems in high-content screening (HCS),
which in turn permits high-content screening. This makes it possible to analyse
several characteristics at the single-cell level and so learn more about the compound
effects (Fox etal. 2006). A lot of data is gathered and stored by automated systems.
In order to handle, analyse, and interpret these data and assist researchers in making
defensible conclusions, bioinformatics tools can be included.
For big compound libraries, automation helps with the tracking, retrieval, and
storage of chemical compounds. It guarantees that samples are ready for screening
at any time. Automated methods can be utilized for follow-up assays, such as doseresponse studies, selectivity testing, and lead optimization, once hits have been
identied in primary screens (Wildey etal. 2017). 3D drug screening is also made
possible by robotic systems’ ability to handle 3D spheroids and cell culture models,
which enables more physiologically accurate drug testing. Automation is helpful for
combination screens, which examine different combinations of chemicals to nd
synergistic effects, and for repurposing of already-approved medications for new
applications.
By minimizing human exposure to potentially dangerous compounds, automated
systems improve safety. They are capable of handling substances that need certain
environmental conditions or containment (Du etal. 2020). High-throughput phenotypic screening, in which chemicals are evaluated according to their impact on the
phenotype of cells or organisms that are being examined, is making a comeback
thanks to automation and robots. This method frequently nds targets and mechanisms that are hidden from view in conventional target-based displays.
Automated HTS can be used to realign current medications for novel conditions,
hence reducing development time and costs. The ability of robotic systems to run
constantly makes screening possible around the clock, which is necessary for quick,
extensive HTS campaigns (Datta etal. 2018). The drug discovery process has been
greatly expedited by the incorporation of automation and robotics in HTS, enabling
researchers to efciently and precisely screen millions of molecules. This technical
breakthrough leads to the development of novel and life-saving drugs by speeding
up the identication of possible drug candidates and lowering the cost of drug
228
https://t.me/med1917
research. Automation and robots in HTS will continue to be at the forefront of pharmaceutical research as long as technology keeps developing.
J. Sundarasekar and G. Sahgal
11.6.2 Combining Genomics andProteomics
withHigh-Throughput Screening
High-throughput screening (HTS) has been transformed by the merging of genomes
and proteomics, which offers a comprehensive strategy to nd and evaluate prospective drug targets, explore chemical interactions, and expedite the development
of novel treatments. This combination improves drug discovery’s effectiveness and
success rates in a number of ways (Bleicher etal. 2003).
In genomics, genes and genetic variants linked to diseases can be identied using
genomic data. These observations provide a basis for determining possible therapeutic targets. By verifying proteomic targets’ existence and importance at the protein level, proteomic data can aid in their validation. It enables scientists to determine
if the expression of a gene results in a functioning protein and whether that protein
is a promising target for therapy.
Under the biomarker discovery mechanism, genetic markers found by genomics
may be used as prospective illness biomarkers. These markers can be used to track
the course of an illness or evaluate how well a treatment is working. Proteomic
proling is able to recognize particular proteins or protein patterns as biomarkers
that signify the occurrence, development, or response to therapy of a given disease.
For drug target identication, combining the strengths of proteomics and genomics allows for a thorough understanding of a disease’s molecular landscape. Finding
the most potential pharmacological targets may result from combining genetic and
protein expression data. Using mechanism of action (MoA) studies, proteomic
methods can show how medications or other substances interact with particular
proteins in a cell. Understanding a compound’s molecular weight at equilibrium is
essential for medication development. Researchers can evaluate the effects of substances on several biological parameters at the cellular or subcellular level by combining high-content screening with proteomics and genomics. This method offers a
more thorough understanding of chemical action.
Genetic differences unique to each patient that affect how they respond to treatment can be found using genomic data. By identifying patient-specic patterns of
protein expression, proteomic data might help doctors customize a patient’s course
of care. Additionally, compounds that particularly target genes or genetic variations
linked to disease can be found using genomic data. Information pertaining to the
expression and function of particular proteins within cells can then be inferred from
proteomic data.
Proteomic and genomic methods help with lead optimization by determining and
dening the most promising compounds for additional research and development.
Combining HTS with other analytical tools enables the evaluation of a compound’s
Соседние файлы в папке Библиотека им академика М.И. Перельмана